RT Journal Article
A1 Dawood, Fatimah S.
A1 Payne, Amanda B.
A1 McMorrow, Meredith L.
T1 Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus
JF JAMA
JO JAMA
YR 2024
DO 10.1001/jama.2024.5859
SN 0098-7484
AB Immunizations for respiratory syncytial virus (RSV) were newly licensed and recommended for 3 populations in the US in 2023, marking a historic turning point in the prevention of RSV illness in both young children and older adults. First discovered in 1956, RSV has long been recognized as a leading cause of acute respiratory illnesses in young children, resulting in an estimated 58 000 to 80 000 hospitalizations in children younger than 5 years of age each year in the US, with infants at greatest risk of hospitalization. Respiratory syncytial virus has also been increasingly recognized as a cause of severe acute respiratory illness in older adults and is estimated to cause 60 000 to 160 000 hospitalizations and 6000 to 10 000 deaths annually among adults aged 65 years or older in the US. Until 2023, only palivizumab (a monoclonal antibody requiring monthly dosing) was available for RSV prevention for eligible infants and young children with certain underlying conditions that increase risk of severe RSV illness.
RD 5/20/2024
UL https://doi.org/10.1001/jama.2024.5859